C5 and paroxysmal nocturnal hemoglobinuria: Among new anti‐complement therapies, Ravulizumab (Ultomiris) is a potent and selective C5 inhibitor, approved by FDA and EMA; it is indicated for the treatment of PNH, atypical haemolytic uremic syndrome, generalized myasthenia gravis and Neuromyelitis optica spectrum disorder.